LRRK2-mutant microglia trigger dopaminergic neurodegeneration when activated by neuromelanin

Lucas Blasco-Agell,Meritxell Pons Espinal,Veronica Testa,Gerard Roch,Jara Montero-Mu,Irene Fern,Valentina Baruffi,Marta Gonzalez-Sepulveda,Yvonne Richaud-Patin,Senda Jim,Thais Cuadros,Joana M. Cladera-Sastre,Joan Compte,Manel Juan Otero,Eduardo Tolosa,Angel Raya,Miquel Vila,Antonella Consiglio

DOI: https://doi.org/10.1101/2024.10.07.616997

2024-10-07

Abstract:Parkinson's disease (PD) is a progressive and yet incurable neurodegenerative condition characterized by loss of neuromelanin-containing dopamine neurons in the substantia nigra of the midbrain. The contribution of non-neuronal cells to neuron degeneration in PD is receiving increasing attention. Here, we generated functional microglia-like cells from induced pluripotent stem cells (iPSC) from patients with PD associated to LRRK2 mutations, the most common cause of genetic PD, along with their gene-corrected isogenic controls and with iPSC from healthy donors. Microglia-like cells of either genotype did not induce neurodegeneration of healthy dopamine neurons in co-culture experiments. However, LRRK2-mutant microglia became hyperreactive upon LPS stimulation when compared with controls, as judged by cytokine expression profile, production of reactive oxygen species. We then tested a-synuclein and neuromelanin as potential endogenous stimuli for activating mutant microglia. Upon exposure to neuromelanin-containing particles, but not to preformed a-synuclein fibrils, LRRK2-mutant microglia induced the degeneration of healthy dopamine neurons, in a process that could be prevented by pre-treatment with the immunomodulatory drug ivermectin. Finally, the analysis of post-mortem midbrain tissue of LRRK2-PD patients found increased numbers of activated microglia cells in close contact with neuromelanin-containing neurons. Taken together, our findings uncover a potential critical role of neuromelanin-activated microglia in the context of PD progression, and provide an experimental model of PD to test new therapeutic targets.

Cell Biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the neurodegenerative mechanism related to LRRK2 mutations in Parkinson's disease (PD), especially exploring whether LRRK2 - mutated microglia will lead to the degeneration of dopaminergic neurons when stimulated by neuromelanin (NM). Specifically, by generating induced pluripotent stem cell (iPSC) - derived microglia - like cells carrying LRRK2 mutations and observing the behavior of these cells under different conditions, the researchers aim to reveal:

1. **Activity of LRRK2 - mutated microglia**: Study the changes in the activity of LRRK2 - mutated microglia under unstimulated and stimulated (such as LPS, NM, etc.) conditions, including cytokine production and reactive oxygen species (ROS) release.

2. **Effect of NM on LRRK2 - mutated microglia**: Evaluate whether NM can activate LRRK2 - mutated microglia and cause it to over - react, thereby affecting the survival of dopaminergic neurons.

3. **Role of immunomodulatory drugs**: Test whether the immunomodulatory drug Ivermectin (IVM) can prevent the degeneration of dopaminergic neurons caused by NM - activated LRRK2 - mutated microglia.

4. **Pathological verification**: Verify the clinical relevance of in vitro experimental results by analyzing the post - mortem brain tissues of patients with LRRK2 - mutated PD, especially observing whether there are more activated microglia in these patients' brains and whether these cells are related to neuromelanin granules.

Overall, this paper aims to explore the potential role of LRRK2 - mutated microglia in the progression of Parkinson's disease, especially the behavior of these cells when stimulated by neuromelanin and their impact on dopaminergic neurons, thereby providing new targets and strategies for the treatment of Parkinson's disease.